PharmaCyte invests $7M in MyMD for convertible preferred stock and warrants

PharmaCyte Biotech, Inc.

Invests $7M for Series G Convertible Preferred Stock convertible into 3,854,626 MyMD common shares at $1.816 per share.
Also receives warrants to purchase up to 3,854,626 MyMD common shares (5-year and 18-month terms) at $1.816 per share.
Gets right to nominate one board member while owning >20% of MyMD common stock on as-converted basis.
MyMD filed Certificate of Designations for Series G Preferred with 10% annual dividend, compounded monthly.
MyMD is a clinical-stage biopharma with Phase 2 data in sarcopenia (MYMD-1) and advancing toward FDA discussions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.